GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Advance Bio-Pharmaceutical Inc (ROCO:4186) » Definitions » Gross-Profit-to-Asset %

Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Gross-Profit-to-Asset % : 36.23% (As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is Taiwan Advance Bio-Pharmaceutical Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Taiwan Advance Bio-Pharmaceutical's annualized Gross Profit for the quarter that ended in Dec. 2023 was NT$264.3 Mil. Taiwan Advance Bio-Pharmaceutical's average Total Assets over the quarter that ended in Dec. 2023 was NT$729.4 Mil. Therefore, Taiwan Advance Bio-Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 36.23%.


Taiwan Advance Bio-Pharmaceutical Gross-Profit-to-Asset % Historical Data

The historical data trend for Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Advance Bio-Pharmaceutical Gross-Profit-to-Asset % Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.18 17.25 16.24 27.11 27.27

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.97 30.07 25.55 18.72 36.23

Competitive Comparison of Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset % falls into.



Taiwan Advance Bio-Pharmaceutical Gross-Profit-to-Asset % Calculation

Taiwan Advance Bio-Pharmaceutical's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=198.455/( (706.773+748.571)/ 2 )
=198.455/727.672
=27.27 %

Taiwan Advance Bio-Pharmaceutical's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=264.256/( (710.254+748.571)/ 2 )
=264.256/729.4125
=36.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Taiwan Advance Bio-Pharmaceutical Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Taiwan Advance Bio-Pharmaceutical's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Business Description

Traded in Other Exchanges
N/A
Address
12F., No.25, Ln. 169, Kangning Street, Xizhi Dist, New Taipei City, TWN, 22180
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's product includes Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.

Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Headlines

No Headlines